Lab-grown diamond device might change how we measure radiation doses
Peer-Reviewed Publication
Updates every hour. Last Updated: 22-Jun-2026 04:16 ET (22-Jun-2026 08:16 GMT/UTC)
Tokyo, Japan – A team led by researchers from Tokyo Metropolitan University, in collaboration with Tohoku University and Orbray Co., Ltd., using heteroepitaxial diamond materials developed by Orbray, have shown that lab-grown diamonds might realize a radiation dosimeter compatible with both medical diagnosis and radiation therapy. They demonstrated that a diamond-based dosimeter could accurately measure doses in the same energy range as diagnostic X-rays, with far better sensitivity per volume than conventional detectors. Using the same device for dosimetry during both diagnosis and therapies could enable improved consistency.
Liver organoids, three-dimensional structures derived from stem cells or hepatic progenitors, have emerged as a transformative technology. Unlike traditional two-dimensional cultures or animal models, organoids faithfully recapitulate the complex architecture and functionality of native liver tissue. This review summarizes recent advancements in liver organoid technology, detailing their development, classification, and key applications.
New research from MUSC Hollings Cancer Center highlights a promising new approach to smoking cessation by targeting the brain’s executive control system. In a randomized clinical trial led by Hollings researcher Xingbao Li, M.D., noninvasive brain stimulation aimed at the dorsolateral prefrontal cortex helped participants reduce smoking and suppress cravings more effectively than other targeting approaches.
The findings suggest that strengthening brain regions involved in decision-making and self-control may help people to better manage the urge to smoke. The work adds to growing efforts at Hollings to expand evidence-based tobacco treatment options and better understand the brain mechanisms underlying addiction.
Scientists have long suspected that androgens, male sex hormones like testosterone, may help tumors grow because the hormones can suppress immune responses to some cancers. New research from the lab of Cleveland Clinic's Justin Lathia, PhD, provides a different viewpoint: testosterone helps slow the growth of glioblastoma in men.
The article, published in Nature, observes that blocking testosterone makes tumors grow faster—which aligns with trends observed in male glioblastoma patients. Along with changing the narrative around the inclusion of testosterone in cancer treatment, the findings highlight that when it comes to therapeutics, tumor location is a crucial factor.